Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Simvastatin
Drug ID BADD_D02026
Description Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,[A181421] which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. The clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America.[A181087, A181406] Simvastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [lovastatin] are considered first-line options for the treatment of dyslipidemia.[A181087, A181406] Increasing use of the statin class of drugs is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease, and stroke, has become a leading cause of death in high-income countries and a major cause of morbidity around the world.[A181084] Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, [rosuvastatin] is considered the most potent; doses of 10 to 40mg [rosuvastatin] per day were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while simvastatin has been found to have an average decrease in LDL-C of ~35%.[A181409,A181535,A181538,A1793] Potency is thought to correlate to tissue permeability as the more lipophilic statins such as simvastatin are thought to enter endothelial cells by passive diffusion, as opposed to hydrophilic statins such as [pravastatin] and [rosuvastatin] which are taken up into hepatocytes through OATP1B1 (organic anion transporter protein 1B1)-mediated transport.[A181424,A181460] Despite these differences in potency, several trials have demonstrated only minimal differences in terms of clinical outcomes between statins.[A181438, A181427]
Indications and Usage For the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It can also be used in adolescent patients for the treatment of heterozygous familial hypercholesterolemia.
Marketing Status Prescription; Discontinued
ATC Code C10AA01
DrugBank ID DB00641
KEGG ID D00434
MeSH ID D019821
PubChem ID 54454
TTD Drug ID D0H0ND
NDC Product Code 65841-065; 70377-002; 55111-198; 71610-615; 68071-1965; 61919-710; 24658-503; 68071-3289; 55111-268; 71205-070; 50090-3922; 68071-4998; 70377-004; 29273-402; 71335-1906; 51846-1021; 50090-4801; 63629-3393; 60312-0726; 65862-050; 61919-688; 42571-020; 50090-1121; 68180-480; 50090-5019; 16729-006; 73377-135; 42658-111; 68788-9747; 70518-1426; 63629-3392; 60312-0740; 61919-446; 16729-005; 70377-003; 31722-510; 71610-050; 63739-573; 70518-1860; 71335-1891; 55154-8136; 60312-0749; 50090-4897; 65862-052; 24658-504; 43063-080; 50090-1277; 70518-0583; 52343-021; 65862-054; 71205-192; 53002-1527; 63187-075; 43353-858; 68071-2559; 60687-210; 60312-0009; 42571-040; 68788-9868; 68180-482; 60760-006; 50090-5788; 52343-023; 52343-025; 70377-005; 65841-067; 68788-9869; 60312-0735; 31722-513; 60760-019; 71610-623; 13403-201; 31722-514; 68071-2336; 16714-682; 70518-0060; 70518-0064; 24658-500; 43063-726; 68071-4996; 65862-051; 55111-197; 63629-1199; 50090-2543; 68645-470; 68071-4504; 42708-148; 68645-527; 71610-610; 68180-464; 50090-4901; 68071-2560; 63629-3385; 61919-431; 78206-182; 50090-3473; 71610-622; 42658-108; 50090-1000; 65841-066; 63629-3408; 65841-069; 13632-401; 78206-181; 51927-0015; 68382-066; 68180-479; 68554-0099; 55154-4782; 65372-1107; 68788-9429; 67296-0750; 63629-1197; 65862-221; 65727-002; 42658-109; 70518-3349; 55111-200; 58623-0049; 68071-1711; 43353-664; 63739-572; 53002-1528; 63187-191; 43063-008; 68382-069; 71610-609; 70377-001; 43353-861; 53002-1569; 42571-010; 0615-8056; 50090-5531; 50090-4736; 16729-156; 63187-449; 43353-007; 55111-199; 65841-068; 43063-162; 68180-481; 68071-1646; 63629-1198; 68382-065; 24658-501; 68382-068; 68180-465; 63629-1196; 78206-180; 68382-067; 71610-611; 43063-733; 63629-1200; 43063-727; 70518-0061; 29273-401; 68071-3090; 68084-511; 63629-7421; 78206-179; 31722-512; 68180-478; 16729-004; 68071-2628; 42658-110; 71335-1905; 42571-080; 52343-024; 31722-511; 16729-007; 42571-005; 58623-0125; 0615-7993; 16714-685; 60760-005; 61919-764; 0615-7992; 68084-512; 24658-502; 63739-571; 13632-402; 63739-570; 65862-053; 68554-0010; 68071-1990; 68071-1946; 71610-250; 43353-856; 52343-022; 16714-684; 16714-683; 16714-681; 50090-0999
Synonyms Simvastatin | Zocor | MK-733 | MK 733 | MK733 | Synvinolin
Chemical Information
Molecular Formula C25H38O5
CAS Registry Number 79902-63-9
SMILES CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Acute myocardial infarctionStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
Angina pectorisStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
AngioplastyStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
ArteriosclerosisLiver carboxylesterase 1P23141T763699420339; 14660992; 14998629; 14984434
Cerebrovascular accidentStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
DeathStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
Myocardial ischaemiaApolipoprotein EP02649T2168910736278; 7605354
Nephropathy toxicVariant-surface-glycoprotein phospholipase CP09194Not Available6092605; 6307156; 6276533; 3566282; 8663028; 3164751; 2623196; 7876334; 2159723; 8498544; 12039977
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.0010.000658%
Abdominal pain07.01.05.0020.000658%
Abdominal pain lower07.01.05.010--Not Available
Abdominal pain upper07.01.05.003--
Abdominal rigidity07.01.05.0110.000046%Not Available
Abnormal dreams19.02.03.001; 17.15.02.0010.000276%Not Available
Abortion18.01.01.0010.000046%Not Available
Abortion spontaneous18.01.04.001--Not Available
Acute hepatic failure09.01.03.0010.000128%Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.001--Not Available
Acute psychosis19.03.01.0010.000122%Not Available
Acute pulmonary oedema22.01.03.005; 02.05.02.0040.000046%Not Available
Ageusia17.02.07.001; 07.14.03.0030.000138%Not Available
Aggression19.05.01.0010.000276%Not Available
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.0030.000490%
Alcohol problem19.07.02.0130.000046%Not Available
Alopecia23.02.02.001--
Alopecia totalis23.02.02.0060.000031%Not Available
Altered state of consciousness19.07.01.003; 17.02.04.001--Not Available
Amnesia19.20.01.001; 17.03.02.0010.000888%
Amyotrophic lateral sclerosis17.05.05.0040.000031%Not Available
Anaemia01.03.02.001--
Anal fissure07.03.01.0020.000031%
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angina unstable24.04.04.004; 02.02.02.0040.000046%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 28 Pages